



THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF YOU DO NOT UNDERSTAND IT OR ARE IN DOUBT AS TO THE ACTION TO BE TAKEN, PLEASE CONSULT YOUR STOCKBROKER, ACCOUNTANT, SOLICITOR, FINANCIAL ADVISER OR WEALTH MANAGER IMMEDIATELY.

Date: 27 August 2026

Dear Investor,

A New Brand and Changes to AXA Framlington Health Fund (the "Fund")

We, AXA Investment Managers UK Limited, are writing to you in our role as the Authorised Fund Manager of the Fund.

The purpose of this letter is to inform you of some planned changes to the Fund. Although the changes do not require unitholder approval, and you are not required to take any action, we recommend that you read this letter carefully.

The Financial Conduct Authority ("**FCA**") has been notified of the changes and has confirmed that they will not affect the ongoing authorisation of the Fund. Under the FCA's Rules, you are entitled to a minimum of 60 days' advance notice of the changes because we regard the investment policy aspects of them as "significant" for the purposes of the Rules, and this letter constitutes that notice.

What is changing?

The name and the investment policy and benchmark of the Fund will change as described below. As explained, however, the Fund's core investment philosophy, process and risk profile will remain unaltered after the changes take effect.

Branding and Name Changes

First, you may be aware that in July 2025 AXA Investment Managers was acquired by BNP Paribas. We have been operating within the enlarged BNP Paribas Asset Management group since the start of this year, using its branding on our fund literature, investor communications and website. We are now announcing that, as part of the next stage of the rebranding, AXA Investment Managers UK Limited's name will be changed to "**BNP PARIBAS ASSET MANAGEMENT (UK) Limited**".

Also as part of the reorganisation, the names of the Funds which we manage are being changed so that they align with BNP Paribas branding and naming conventions. In the case of the Fund, its new name will reference "Innovators" in order to emphasise the Fund's focus on companies that use innovative technologies to drive developments in health care, as explained below in the changes to the investment strategy. Consequently, the name of the Fund will change as set out below:

Current Name	New Name
AXA Framlington Health Fund	BNP Paribas AM(UK) Health Care Innovators Fund

AXA Investment Managers UK Limited
22 Bishopsgate, London EC2N 4BQ, United Kingdom
Telephone: +44 (0) 20 7003 1000
www.bnpparibas-am.com/

Registered in England and Wales no 01431068. Registered office as above.
Authorised and regulated by the Financial Conduct Authority and a member of the Investment Association

Following their implementation on **30 November 2026**, these changes will be reflected in the Fund's legal documents and in our reporting and other communications with investors.

Investment Policy Changes

Second, and as a consequence of our integration within the BNP Paribas Group, we are making some changes (i) to provide further detail on the investment strategy the Fund will follow, and (ii) relating to the environmental, social and governance (**ESG**) criteria which are applied as part of the Fund's investment policy.

Investment Strategy

We are amending the investment policy to describe better the Fund's focus on companies that use innovative technologies to drive developments in health care. The Fund will seek to identify and invest in companies that the Manager believes will enable or benefit from innovative technologies. Examples of these technologies include advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology to the healthcare field. This focus will lead to investments in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, and other healthcare services companies. We believe that focusing on companies utilising these types of innovative technologies could lead to better returns for investors in the Fund over the investment horizon of five years or more. The "Health Care Innovators" strategy is a flagship equity strategy of the BNP Paribas Asset Management Group which has benefitted from commercial success, having built up assets under management in the strategy of over £1bn across a broad and diversified client base. The Fund may therefore benefit from a focused sales effort, an increase in assets under management, and potential economies of scale offered by investing in a larger fund should the Fund grow in size. The "Healthcare Innovators" strategy has an established track record that has, on average, delivered stable and attractive risk-adjusted returns for its investors over the long-term.

We estimate that approximately two-thirds of the Fund's assets will be realigned after the change of investment strategy takes effect. However, the resulting portfolio turnover will be managed in the normal course of trading.

At the same time, we will delegate the day-to-day investment management of the Fund to AXA investment Managers US Inc (changing its name to "BNP PARIBAS ASSET MANAGEMENT United States, Inc"), our affiliate located in the US, where many of the technological advances in the health care field originate. The Fund will therefore benefit from longstanding US-based expertise providing close proximity and easier access to a large proportion of the global healthcare investment universe.

Details of the investment strategy changes to the Fund's investment policy are provided for your review in **Appendix 1** to this letter. These changes will take effect from **30 November 2026**.

ESG Criteria

These supplementary changes will update the description of the exclusions and screening methods used, including our ESG scoring framework, as we move to adopt the BNP Paribas Group standards for responsible investment (governed by its Responsible Business Conduct Policy) in place of the AXA Investment Managers guidelines which are currently followed.

The corresponding AXA Investment Managers and BNP Paribas Asset Management policies are closely aligned on ESG-based exclusions and standards. The exclusions applying to equity and fixed income corporates are very compatible in terms of the sectors and issues covered, including on the exclusion of companies based on norms-based screening and standards. There is also a nearly complete match (around 95% of the total number) between the sovereign issuers which are currently excluded and those that will continue to be excluded when the changes take effect. There are just two sovereign issuers which we exclude currently and which will become eligible, in certain restricted circumstances, but these are emerging markets in which the Fund is highly unlikely to invest.

Also, the aim and effect of the ESG scoring methodology will remain the same, with no change (under the BNP Paribas Asset Management policy) to the purpose or influence of a company's ESG score in the overall investment decision-making process. We will continue to use MSCI as the primary external data provider for scoring corporate issuers (equities and fixed income holdings), with Beyond Ratings (a new external provider) and internal fundamental analysis as the primary inputs for sovereign issuers' scores going forward.

These further changes to the Fund's investment policy will take effect from **11 January 2027**. Details are provided for your review in **Appendix 2** to this letter.

Change of Benchmark

Third, the benchmark for the Fund will change as follows:

Current Benchmark	New Benchmark
MSCI World Healthcare Index	MSCI World Healthcare 10/40 Index

We consider that the new benchmark will be a more appropriate performance comparator for the Fund in future. The new benchmark is designed to measure the performance of the health care sector, and it better reflects the key financial characteristics of the Fund as well as taking into account certain concentration constraints to which UCITS funds are subject.

The benchmark change will not materially affect the way in which the Fund is managed. This change will take effect from **30 November 2026**.

Will the investment policy changes result in a change to the Fund's investment objective or risk profile?

No, the changes described in this notification are being made to align the Fund with BNP Paribas Group processes, and there will be no material change in practice to how the Fund is managed. The investment policy changes will not alter the Fund's investment objective or risk profile.

When will the changes take effect?

As detailed above, the naming, investment strategy and benchmark changes will take effect on 30 November 2026. The ESG criteria changes to the Fund's investment policy will be effective from 11 January 2027.

What is the cost of making these changes?

We will meet the costs of amending the Fund's documentation to reflect the changes described in this letter and the costs associated with notifying unitholders.

The costs of realignment of the Fund's assets as a result of the changes outlined above (such as transaction costs and taxes) will be met by the Fund. It is anticipated that such costs should not exceed 0.075% of the current value of the Fund, which, for illustrative purposes only, would amount to a cost of around £0.75 for every £1,000 invested in the Fund. However, the portfolio manager will aim to minimise any implicit transaction costs which may be incurred by the Fund by taking advantage of subscriptions and redemptions and spreading the trading required for the realignment of assets over a period after 30 November 2026.

Further Information

The Prospectus for our range of Authorised Unit Trusts (the "**Prospectus**") and the Fund's Key Investor Information documents ("**KIIDs**") will be amended and republished to reflect the coming into effect of the changes described in this notification. Copies of the Prospectus, the KIIDs, and the Consumer Facing Disclosure document which provides investors with information regarding the sustainability characteristics of the Fund (the "**CFD**") are available on our website <https://www.axa-im.co.uk>.

Should you have any questions about the changes being made or any other aspect of the Fund, or would like to request a copy of the KIID(s) or the CFD, please contact our Customer Services team by phone on 0345 777 5511 (Monday to Friday 9.00am - 5.30pm) or via email on axa-im@uk.dstsyste.ms.com. Alternatively, please contact your usual local representative.

Yours sincerely



Oujnat Karim, Director
For and on behalf of
AXA Investment Managers UK Limited



Guy Davies, Director
For and on behalf of
AXA Investment Managers UK Limited

Appendix 1 Changes to the Investment Policy of the Fund with effect from 30 November 2026

The investment policy of the Fund will be amended as set out below.

Current Investment Policy	Amended Investment Policy
The Fund invests in shares of listed healthcare companies including producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world albeit the Fund tends to be biased towards the US, as this is where the majority of healthcare related companies are based. The Manager selects shares based upon its analysis of a company's financial status, the quality of its management, its expected profitability and prospects for growth. While the Fund does not pursue a specific sustainability objective, it avoids investing in companies which present excessive degrees of environmental, social and governance (ESG) risk. To avoid investing in companies which present excessive degrees of ESG risk, and as part of its responsible investment approach, the Manager will filter and define the Fund's investment universe by: (i) applying AXA Investment Managers' sector-specific investment guidelines relating to responsible investment. Such guidelines exclude investment in soft commodity derivatives or exposure to certain companies based on their involvement in specific sectors (such as tobacco production, natural ecosystem conversion and deforestation, controversial weapons and climate risks); and (ii) applying the AXA Investment Managers ESG Standards policy. This policy excludes: (a) companies involved in the manufacture of white phosphorus weapons, or which fail to meet certain criteria relating to human rights and anti-corruption as well as other ESG	The Fund invests at least 75% of its assets in shares of listed healthcare companies that enable or benefit from innovative technologies including, but not limited to, advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology to the healthcare field. Such companies could include producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, software providers and other healthcare services companies. The Fund invests in companies of any size which can be based anywhere in the world albeit the Fund tends to be biased towards the US, as this is where the majority of healthcare related companies are based. The Manager selects shares based upon its analysis of a company's financial status, the quality of its management, its expected profitability and prospects for growth. While the Fund does not pursue a specific sustainability objective, it avoids investing in companies which present excessive degrees of environmental, social and governance (ESG) risk. To avoid investing in companies which present excessive degrees of ESG risk, and as part of its responsible investment approach, the Manager will filter and define the Fund's investment universe by: (i) applying AXA Investment Managers' sector-specific investment guidelines relating to responsible investment. Such guidelines exclude investment in soft commodity derivatives or exposure to certain companies based on their involvement in specific sectors (such as tobacco production, natural ecosystem conversion and deforestation, controversial weapons and climate risks); and (ii) applying the AXA Investment Managers ESG Standards policy. This policy excludes: (a) companies involved in the

factors; (b) companies which cause, contribute, or are linked to violations of international norms and standards in a material manner or which are involved in incidents and/or events that pose a severe business or reputational risk to the relevant company due to the impact of its involvement on stakeholders or the environment; and (c) companies with the lowest ESG scores, being any score below 1.43 (out of a maximum score of 10), reflecting the worst ESG practices. When selecting investments for the Fund, the Manager will consider a company's ESG score within its broader analysis of the company, where applicable. The Manager believes that companies with higher or improving ESG scores may be expected to manage risk associated with ESG issues more effectively, which may be expected to contribute to the better financial performance of such companies in the long term. The ESG score is, however, just one component of the Manager's investment process and is not the sole driver of the investment decision-making process. ESG scores are obtained from the Manager's selected external provider(s) as detailed in the "Responsible Investment" section of this Prospectus and may be adjusted by the Manager (or created by the Manager where an external score is not available), in each case using its own research. It is possible, however, that there will not be an ESG score for an investment in a limited number of cases. The AXA Investment Managers ESG Standards policy and AXA Investment Managers' sector-specific investment guidelines are subject to change. The latest copies are accessible via the links provided in the "Responsible Investment" section and are also available from the Manager on request. The Manager undertakes engagements with investee companies with the aim of preserving or enhancing long-term value and creating better ESG outcomes for its investors over the long-term. Engagement is typically conducted at the firm level, rather than on an individual portfolio basis, and seeks to influence better ESG practices within investee companies in which AXA Investment Managers has the largest	manufacture of white phosphorus weapons, or which fail to meet certain criteria relating to human rights and anti-corruption as well as other ESG factors; (b) companies which cause, contribute, or are linked to violations of international norms and standards in a material manner or which are involved in incidents and/or events that pose a severe business or reputational risk to the relevant company due to the impact of its involvement on stakeholders or the environment; and (c) companies with the lowest ESG scores, being any score below 1.43 (out of a maximum score of 10), reflecting the worst ESG practices. When selecting investments for the Fund, the Manager will consider a company's ESG score within its broader analysis of the company, where applicable. The Manager believes that companies with higher or improving ESG scores may be expected to manage risk associated with ESG issues more effectively, which may be expected to contribute to the better financial performance of such companies in the long term. The ESG score is, however, just one component of the Manager's investment process and is not the sole driver of the investment decision-making process. ESG scores are obtained from the Manager's selected external provider(s) as detailed in the "Responsible Investment" section of this Prospectus and may be adjusted by the Manager (or created by the Manager where an external score is not available), in each case using its own research. It is possible, however, that there will not be an ESG score for an investment in a limited number of cases. The AXA Investment Managers ESG Standards policy and AXA Investment Managers' sector-specific investment guidelines are subject to change. The latest copies are accessible via the links provided in the "Responsible Investment" section and are also available from the Manager on request. The Manager undertakes engagements with investee companies with the aim of preserving or enhancing long-term value and creating better ESG outcomes for its investors over the long-term. Engagement is
---	---

stakes, to maximise its contribution to the achievement of specific ESG objectives across the AXA IM Group. However, where relevant, engagement may be undertaken by the portfolio manager of the Fund. Where an engagement takes place with a company held by the Fund, the Manager expects that this will lead to an enhancement in such company's ESG outcomes, and therefore support the long-term profitability of the company, and in turn, the achievement of the Fund's objective. Where weaknesses are identified, the Manager may consider the use of escalation techniques (such as voting against certain resolutions presented by management at general meetings) in certain cases. More details on the Manager's approach to engagement with companies are available on the website <https://www.axa-im.co.uk/> under the heading "Responsible Investing".

If the Manager deems that an investment no longer meets the criteria set out in this investment policy or its expectations in terms of that investment's prospects for achieving the Fund's objective, the Manager will disinvest as soon as practicable having regard to the best interests of the Fund's investors and in accordance with its best execution policy.

The Fund may also invest in other transferable securities and units in collective investment schemes (including schemes that are managed by the Manager or its associates). The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.

typically conducted at the firm level, rather than on an individual portfolio basis, and seeks to influence better ESG practices within investee companies in which AXA Investment Managers has the largest stakes, to maximise its contribution to the achievement of specific ESG objectives across the AXA IM Group. However, where relevant, engagement may be undertaken by the portfolio manager of the Fund. Where an engagement takes place with a company held by the Fund, the Manager expects that this will lead to an enhancement in such company's ESG outcomes, and therefore support the long-term profitability of the company, and in turn, the achievement of the Fund's objective. Where weaknesses are identified, the Manager may consider the use of escalation techniques (such as voting against certain resolutions presented by management at general meetings) in certain cases. More details on the Manager's approach to engagement with companies are available on the website <https://www.axa-im.co.uk/> under the heading "Responsible Investing".

If the Manager deems that an investment no longer meets the criteria set out in this investment policy or its expectations in terms of that investment's prospects for achieving the Fund's objective, the Manager will disinvest as soon as practicable having regard to the best interests of the Fund's investors and in accordance with its best execution policy.

The Fund may also invest in other transferable securities and units in collective investment schemes (including schemes that are managed by the Manager or its associates). The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.

Appendix 2

Further Changes to the Investment Policy of the Fund with effect from 11 January 2027

The investment policy of the Fund will be amended as set out below.

Amended Investment Policy

The Fund invests at least 75% of its assets in shares of listed healthcare companies that enable or benefit from innovative technologies including, but not limited to, advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology to the healthcare field. Such companies could include producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, software providers, and other healthcare services companies. The Fund invests in companies of any size which can be based anywhere in the world albeit the Fund tends to be biased towards the US, as this is where the majority of healthcare related companies are based. The Manager selects shares based upon its analysis of a company's financial status, the quality of its management, its expected profitability and prospects for growth.

While the Fund does not pursue a specific sustainability objective, it avoids investing in issuers which present excessive degrees of environmental, social and governance (ESG) risk. Accordingly, the Manager will filter and define the Fund's investment universe by systematically applying BNP Paribas Asset Management's firm-wide approach to ESG integration, including the Responsible Business Conduct Policy exclusions and scoring framework described below, and stewardship.

BNP Paribas Asset Management's Responsible Business Conduct Policy (the "**RBC Policy**") excludes companies assessed to be in violation of norms and standards relating to human and labour rights, the environment, and / or corruption, as well as companies operating in sensitive sectors (e.g tobacco, coal, unconventional oil and gas, and excluded weapons), as these companies are deemed to cause unacceptable harm to society and / or the environment.

The RBC Policy is subject to change. The latest version is accessible via the link provided in the "Responsible Investment" section and is also available from the Manager on request.

The Manager will consider an issuer's ESG score within its broader analysis of the issuer, where applicable. ESG scores provide a standardized and holistic view on the performance of issuers on ESG factors, applying a scoring methodology based on a combination of criteria covering the most material risks. The Manager believes that issuers with higher or improving ESG scores may be expected to manage risk associated with ESG issues more effectively, which may be expected to contribute to the better financial performance of such issuers in the long term. The Manager will generally exclude companies with the lowest ESG scores, being any score below 1.43 out of a maximum of 10, reflecting the worst ESG practices. The ESG score is, however, just one component of the Manager's investment process and is not the sole driver of the investment decision-making process.

ESG scores are obtained as detailed in the "Responsible Investment" section of this Prospectus. It is possible, however, that there will not be an ESG score for an investment in a limited number of cases. In such cases, or if the Manager disagrees with the score attributed to an issuer by an external data provider, the Manager may allocate to that issuer the Manager's own score based on its own research. Some ESG data may be subjective and change over time. The BNP Paribas Asset Management scoring methodology described above may evolve in future to take into account factors such as changes in data availability and reliability, regulatory developments, or other external frameworks and initiatives.

The Manager undertakes engagements with investee issuers with the aim of preserving or enhancing long-term value and creating better ESG outcomes for its investors over the long-term. Engagement is typically conducted at the firm level, rather than on an individual portfolio basis, and seeks to influence better ESG practices within investee issuers, to maximise the contribution to the achievement of specific ESG objectives across the BNP Paribas Asset Management Group. However, where relevant, engagement may be undertaken by the portfolio manager of the Fund. Where an engagement takes place with an issuer held by the Fund, the Manager expects that this will lead to an enhancement in such issuer's ESG outcomes, and therefore support the long-term profitability of the issuer, and in turn, the achievement of the Fund's objective. Where weaknesses are identified, the Manager may consider the use of escalation techniques (such as voting against certain resolutions presented by management at general meetings) in certain cases. More details on the Manager's approach to engagement with companies are available on the website <https://www.axa-im.co.uk/> under the heading "Responsible Investing".

If the Manager deems that an investment no longer meets the criteria set out in this investment policy or its expectations in terms of that investment's prospects for achieving the Fund's objective, the Manager will disinvest as soon as practicable having regard to the best interests of the Fund's investors and in accordance with its best execution policy.

The Fund may also invest in other transferable securities and units in collective investment schemes (including schemes that are managed by the Manager or its associates). The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.